Floatz logo

bay1093884

Hemophilia

BayerPhase 1Dormant
CC
41/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
81/ 100

Competitive context

16 Active assets in the Hemophilia cohort.

Asset / SponsorPhaseRating
Ribavirin
Kenneth Sherman
Phase 4BB
Pegylated Interferon Alpha2A
Baqiyatallah Medical Sciences University
Phase 4BB
Eptacog Alfa
Laboratoire français de Fractionnement et de Biotechnologies
Phase 3BB
Fitusiran
Sanofi
Phase 3BB
Pcc
Institute of Hematology & Blood Diseases Hospital, China
Phase 4B

View all 33 →

Same molecule, other indications

bay1093884 is also rated in:

Hemophilia A and BDormant
CCC
Indicative ·
52 / 100
View asset →
Hemophilia BDormant
CC
Indicative ·
44 / 100
View asset →
Hemophilia ADormant
CC
Indicative ·
42 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →